XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVERSE MERGER (Pro-forma Disclosures) (Details) - Transgenomics - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Business Acquisition [Line Items]    
Net sales $ 1,742 $ 2,605
Net loss available to common stockholders $ (22,980) $ (15,838)
Loss per common share (in dollars per share) $ (3.40) $ (2.48)